SCO-267

Cat. No.:	HY-132265		
CAS No.:	1656261-09)-4	
Molecular Formula:	$C_{36}H_{46}N_4O_5$		
Molecular Weight:	614.77		
Target:	Free Fatty A	Acid Rece	ptor
Pathway:	GPCR/G Pro	otein	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
	1 mM	1.6266 mL	8.1331 mL	16.2662 mL	
	5 mM	0.3253 mL	1.6266 mL	3.2532 mL	
	10 mM	0.1627 mL	0.8133 mL	1.6266 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.		
In Vivo	1. Add each solvent Solubility: ≥ 2.5 m	one by one: 10% DMSO >> 90% cor g/mL (4.07 mM); Clear solution	n oil		

BIOLOGICAL ACTIV	
Description	SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes ^[1] .
IC ₅₀ & Target	GPR40 ^[1]
In Vitro	SCO-267 (CHO cells) activates the Gα _q , Gα _s , and Gα _{12/13} pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Product Data Sheet

о∕∽он

Animal Model:	N-STZ rats ^[1]
Dosage:	1 or 10 mg/kg
Administration:	P.o.;
Result:	Improved insulin sensitivity and exerted sustained glucose-lowering effect.

CUSTOMER VALIDATION

- Rapid Commun Mass Spectrom. 2022 May 13;e9325.
- Biomed Chromatogr. 2023 May 15;e5685.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293.

Caution: Product has not been fully validated for medical applications. For research use only.